secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulcrum Therapeutics, Inc. (FULC)
CIK:        0001680581
Form:       8-K
Filed at:   2025-12-08T23:59:59+00:00
Accession:  0001193125-25-310509
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulcrum reports positive Phase 1b data for pociredir in SCD: 58% patients achieved HbF>=20% at 20 mg dose
--------------------------------------------------------------------------------

- Mean absolute HbF increased 9.9% at Week 6 in 20 mg cohort (vs 5.6% in 12 mg); 7 of 12 patients (58%) achieved HbF ≥20%.
- Clear dose-response: >3.75-fold mean HbF induction at Week 12 (n=6) vs 2.4-fold in 12 mg cohort.
- Hemolysis markers improved at Week 6: indirect bilirubin -37%, LDH -37%, reticulocyte counts -33%.
- Pociredir well-tolerated with no treatment-related SAEs or discontinuations; dosed in 148 adults to date.
- Plans to submit IND for bone marrow failure syndromes (e.g., Diamond-Blackfan anemia) in Q2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525310509/0001193125-25-310509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680581/000119312525310509/fulc-20251208.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-310509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer